August 2023 CUSTOMIZED PROSTATE CANCER RISK SCREENING USING NOVEL NOMOGRAMS WITH MRIAshley E. Ross, MD, PhD, discusses the novel nomograms he and his team at Northwestern Medicine developed. The nomograms incorporate multiparametric prostate MRI, serum biomarkers and patient clinicodemographic features to help clinicians risk stratify patients with elevated PSA of 2–20 ng/mL who are being considered for biopsy. The nomograms were internally validated and evaluated in an independent cohort of men. The accuracy of the nomograms was high, with areas under the curves (AUC) of ≥0.885 in the training cohort and ≥0.896 in the independent validation cohort.
The nomograms are available here to aid biopsy and treatment decisions: https://rossnm1.shinyapps.io/MynMRIsk... |
Refer a PatientNorthwestern Medicine welcomes the opportunity to partner with you in caring for your patients.
|